(EULAR2014) Which candidate biologics for rheumatology are destined to pass "Go" and collect? A member of the audience at the recent conference presents his observations and comments.
Targeted treatment for psoriatic arthritis, already shown to improve disease activity markers, now associated with low rates of progression in joint erosion.
(EULAR 2014) IgG4-related disorder and Sjögren syndrome share some symptoms, but have different treatments. A new study involving registry and clinical research data shows how to tell them apart.
(EULAR 2014) Rheumatologists and radiologists from 11 countries have collaborated to draft 10 recommendations for imaging to diagnose axial and peripheral spondyloarthritis.
(EULAR 2014) New research finds erectile dysfunction common among gout patients, and distinctive differences between men and women in predisposing factors and treatment risks.
(EULAR 2014) Predictors of continuing pain after rheumatoid arthritis treatment differ from those that predict inflammation. For TNF inhibitors at least, unresolved pain also contributes to treatment failure.
(EULAR 2014) Based on physician's opinions and on some clinical indicators, the BAFF inhibitor belimumab is achieving impressive results against lupus in both the US and Germany.
(EULAR 2014) In a Phase 3 study of the anti-IL6R monoclonal antibody sarilumab, two doses of the drug proved significantly more efficacious than placebo against active rheumatoid arthritis.
(EULAR 2014) Analysis of 7-month results show few problems and great benefit for the Gardasil vaccine against human papilloma virus in girls or young women with juvenile arthritis.
(EULAR 2014) In some patients with early rheumatoid arthritis, the same citrullinated antigens and the corresponding antibodies are present in the lungs and synovial tissues.